Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been proven to be effective in reducing the emergence of kidney failure when combined with RAS inhibition in a diverse population of patients [10,12,13]. This evidence concerns the gene SLC5A2 and kidney failure.